---
category: news
title: "OSE Immunotherapeutics Announces Artificial Intelligence Antibody Drug Development Collaboration with MAbSilico"
excerpt: "NANTES, France--(BUSINESS WIRE)--Regulatory News: OSE Immunotherapeutics (Paris:OSE) (ISIN: FR0012127173; Mn√©mo: OSE), today announced a new collaboration agreement with deep technology innovative start-up MAbSilico, located in Tours, France, to use artificial intelligence (AI)-based solutions for therapeutic antibody drug development."
publishedDateTime: 2020-02-12T17:00:00Z
webUrl: "https://www.businesswire.com/news/home/20200212005609/en/OSE-Immunotherapeutics-Announces-Artificial-Intelligence-Antibody-Drug"
type: article
quality: 17
heat: 17
published: false

provider:
  name: Business Wire
  domain: businesswire.com

topics:
  - AI

images:
  - url: "https://mms.businesswire.com/media/20200212005609/en/545518/23/OSE_LOGO_Horizontal_RVB.jpg"
    width: 1200
    height: 627
    title: "OSE Immunotherapeutics Announces Artificial Intelligence Antibody Drug Development Collaboration with MAbSilico"

secured: "f/H6mMfm+p0Pci7XKjqNyj+JvwJsx33OxoN+Wf+sZSnFgt/m3JEMrZLeYlBWTDBDLGOJ8uHUc/t4hir7nEJ0H9Ug0PbIqXqG4EzGJCX0xc92V4YnDj4uSX5dswbgP3W1l1UISZQ5Pp+U5ltnU+R9ta2Keg7wmjO5AUrvyfNBJqSl7eKO/QVpGX8kSb5ZIDqYqeTFcSOBP1ByQKczlIf1gQjsYipitCQDNqw2zLiGhngLn0z33CNkPe092EuMYHc6QPkRJoXrzQvJcBG1Xofrmx3XeeVJWIsXbpxRgv+pgXpKKfTF1QhmmHfX4SyNwzv71zm3ktAJVugxbKY6dCs8mkFhh++3vz1YbxiWgEClxqtwHT4JSpqFqUYTQJjGpTXaWVTFWf1rDmPptk2lM8oonO1zy71TFZ6WvYnHYOekJJZpe5inESTg3QjIKpM0J5vDBtB0d+sW96ZruT4K1MY/TETkGH1GIKRImfXzIcw2tgM=;UDEcE3CN5alN8jzuSoBtUw=="
---

